Supratentorial and Infratentorial Ependymoma

John Socrates Myseros1,2

  • 1Neurosurgery and Pediatrics, George Washington University School of Medicine, Washington, DC, USA. jmyseros@childrensnational.org.

Insights

Pediatric ependymomas are classified into four molecular subtypes, impacting treatment and outcomes. Understanding these subtypes, like ZFTA and YAP1 fusions, guides individualized therapy for better survival in children.

Area of Science:

  • Pediatric neuro-oncology
  • Molecular neuropathology
  • Radiation oncology

Background:

  • Ependymomas are the third most common pediatric intracranial tumors, affecting various brain compartments.
  • Symptoms and prognosis vary based on tumor size, location, and patient age.
  • Complete surgical resection is the primary determinant of long-term outcomes.

Purpose of the Study:

  • To review current understanding of pediatric intracranial ependymomas.
  • To highlight the impact of molecular subgrouping on diagnosis and treatment strategies.
  • To discuss the evolving therapeutic landscape, including surgery, radiation, and potential immunotherapies.

Main Methods:

  • Review of current literature on pediatric ependymoma diagnosis and treatment.
  • Emphasis on the role of Magnetic Resonance Imaging (MRI) in evaluation and monitoring.
  • Discussion of histopathologic grading (WHO Grade II and III) and molecular subtyping.

Main Results:

  • Four main molecular subtypes (ST-EPN-YAP1, ST-EPN-ZFTA, PF-EPN-A, PF-EPN-B) are identified, influencing prognosis.
  • ZFTA fusion-positive tumors in younger children and type A posterior fossa tumors are associated with poorer outcomes.
  • YAP1 fusion-positive supratentorial ependymomas and type B posterior fossa tumors in older children may be managed with surgery alone.

Conclusions:

  • Molecular subgrouping is revolutionizing the approach to pediatric ependymomas.
  • Individualized treatment strategies based on molecular subtypes are crucial for improving outcomes.
  • Future research may focus on targeted therapies and immunotherapeutic interventions.